Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738047 · ClinicalTrials.gov registry record
Reduction of Adverse Drug Events and Readmissions
A clinical trial of Pharmacogenomic Testing for Medication Management, sponsored by ClinLogic.
- Recruiting
- Registry status
- 280,000
- Enrollment target
- 1
- Study location
NCT02738047 is a study of Pharmacogenomic Testing for Medication Management that is actively recruiting participants, run by ClinLogic. The registered enrollment target is 280,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02738047, a study of Pharmacogenomic Testing for Medication Management, is actively recruiting participants, sponsored by ClinLogic.
- RECRUITING
- Registry status
- 280,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Conditions Studied
Study Locations (1)
Pennsylvania
- MD@Home - York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280,000 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02738047
The ClinicalTrials.gov registry entry for NCT02738047 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 280,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ClinLogic, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacogenomic Testing for Medication Management appearing as the primary indexed condition, and to 0 interventions.
NCT02738047 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02738047 about?
NCT02738047 is a clinical study titled "Reduction of Adverse Drug Events and Readmissions". Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
What is the current status of trial NCT02738047?
This trial is currently recruiting. The enrollment target is 280,000 participants. The study started on 2019-03-15. Estimated completion is 2026-12.
What conditions does trial NCT02738047 study?
This clinical trial studies the following conditions: Pharmacogenomic Testing for Medication Management.
Who is sponsoring clinical trial NCT02738047?
This trial is sponsored by ClinLogic, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738047 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.